Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, ...

This weekend, the FDA released its recommendation for Novavax, a vaccine designed to combat COVID-19. That in itself is not ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

Analysis of hospitalized patients with community-acquired pneumonia (CAP) linked azithromycin to lower mortality and more ...

Overall, women who received a COVID vaccine had a 19% greater risk of increase in menstrual cycle length as compared to ...

Novavax Inc. jumped after US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

In a world of increasing fragmentation and polarisation, the 78th World Health Assembly, starting Monday, will present itself ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

Novavax CEO John Jacobs said in a statement that the approval was a "significant milestone" that solidifies a path for people to access the vaccine. The company missed out on the pandemic vaccine ...

JN.1, a variant of Omicron BA.2.86, emerged in late 2023 with 30 immune-evasion mutations. It spreads more efficiently due to ...